Chromoblastomycosis is a subcutaneous mycosis that remains a therapeutic challenge, with no standard treatment and high rates of relapse. On the basis of our recent discoveries in mouse models, we tested the efficacy of topical applications of imiquimod to treat patients afflicted with this chronic fungal infection. We report results of treatment for the first 4 recipients of topical imiquimod, all of whom displayed a marked improvement of their lesions, both with and without concurrent oral antifungal therapy.
Keywords: Fonsecaea pedrosoi; Imiquimod; antifungal treatment; chromoblastomycosis; innate immunity.
© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America.